Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Novartis posts ASSIST Phase 2 results; two pediatric studies listedJul 21Weekly roundup, 3 itemsatrasentancoartem baby